Seroprevalence of neutralizing antibody among SARS-CoV-2 infected individuals
FENG Yan1, CHEN Yin2, CAI Jian1, PAN Jinren1, SUN Wanwan1, ZHANG Yanjun2, LING Feng1, SUN Jimin1
1. Department of Infectious Disease Control and Prevention, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China; 2. Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou, Zhejiang 310051, China
Abstract：Objective To investigate the seroprevalence and influencing factors of serum neutralizing antibodies among SARS-CoV-2 infected individuals, so as to provide the evidence for developing the health management and COVID-19 vaccination strategy among SARS-CoV-2 infected individuals. Methods Recovered SARS-CoV-2 infected individuals from January 1st, 2020 to February 10th, 2021 in Zhejiang Province were recruited in March 2021. Participants' demographics, underlying diseases, date of definitive diagnosis and severity of clinical symptoms were collected using questionnaire surveys, and serum neutralizing antibody against SARS-CoV-2 was detected using a fluorescent immunoassay. In addition, factors affecting the seropositivity of neutralizing antibody against SARS-CoV-2 were identified using a multivariable logistic regression model. Results A total of 559 SARS-CoV-2 infected individuals were enrolled, including 480 confirmed cases and 79 asymptomatic carriers, with an median (interquartile range) age of 47.00 (22.00) years, and all participants had never received COVID-19 vaccination. The median (interquartile range) duration from diagnosis to serum sampling was 387.00 (11.00) days, and the seroprevalence of neutralizing antibody against SARS-CoV-2 was 83.90%. The serum neutralizing antibody against SARS-CoV-2 was all positive 9 months after diagnosis, and the seroprevalence of neutralizing antibody against SARS-CoV-2 appeared no tendency towards a decline with time within 14 months after diagnosis (P>0.05). Multivariable logistic regression analysis showed that women were 1.892 times (95%CI: 1.169-3.064) more likely to produce serum neutralizing antibodies against SARS-CoV-2 than men, and mild, common and severe/critically ill SARS-CoV-2 infected cases were 2.438 (95%CI: 1.305-4.557), 4.481 (95%CI: 2.318-8.663), and 23.525 (95%CI: 2.990-185.068) times more likely to produce serum neutralizing antibodies against SARS-CoV-2 than asymptomatic carrier, respectively. Conclusions The seroprevalence of neutralizing antibody was 100.00% among SARS-CoV-2 infected individuals within 9 months after diagnosis. Individuals' gender and severity of clinical symptoms correlate with the seroprevalence of neutralizing antibody against SARS-CoV-2.
[1] ESMAEILZADEH A,ELAHI R.Immunobiology and immunotherapy of COVID-19:a clinically updated overview[J].J Cell Physiol 2021,236(4):2519-2543. [2] HANSEN C H,MICHLMAYR D,GUBBELS S M,et al.Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020:a population-level observational study[J].Lancet,2021,397(10280):1204-1212. [3] ARKHIPOVA-JENKINS I,HELFAND M,ARMSTRONG C,et al.Antibody response after SARS-CoV-2 infection and implications for immunity:a rapid living review[J].Ann Intern Med,2021,174(6):811-821. [4] DAN J M,MATEUS J,KATO Y,et al.Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection[J/OL].Science,2021,371(6529)[2022-12-27].http://doi.org/10.1126/science.abf4063. [5] YU J,TOSTANOSKI L H,PETER L,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques[J].Science,2020,369(6505):806-811. [6] World Health Organization.COVID-19 natural immunity-Scientific Brief[EB/OL].[2022-12-27].https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Natural_immunity-2021.1. [7] 中华人民共和国国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL].[2022-12-27].http://www.nhc.gov.cn/cms-search/downFiles/ef09aa4070244620b010951b088b8a27.pdf. [8] NANDAKUMAR V,PROFAIZER T,LOZIER B K,et al.Evaluation of a surrogate enzyme-linked immunosorbent assay-based severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)cPass neutralization antibody detection assay and correlation with immunoglobulin G commercial serology assays[J].Arch Pathol Lab Med,2021,145(10):1212-1220. [9] HE Z,REN L,YANG J,et al.Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan,China:a longitudinal,population-level,cross-sectional study[J].Lancet,2021,397(10279):1075-1084. [10] POLLAN M,PEREZ-GOMEZ B,PASTOR-BARRIUSO R,et al.Prevalence of SARS-CoV-2 in Spain(ENE-COVID):a nationwide,population-based seroepidemiological study[J].Lancet,2020,396(10250):535-544. [11] YANG Y,WANG X,DU R H,et al.Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses[J].Emerg Microbes Infect,2021,10(1):905-912. [12] SEOW J,GRAHAM C,MERRICK B,et al.Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans[J].Nat Microbiol,2020,5(12):1598-1607. [13] FAFI-KREMER S,BRUEL T,MADEC Y,et al.Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France[J/OL].EBioMedicine,2020,59[2022-12-27].http://doi.org/10.1016/j.ebiom.2020.102915. [14] 陈晓玲,姚菲容,陈秋婷,等.37例新冠肺炎患者感染初期血清中和抗体的变化规律及影响因素分析[J].海峡预防医学杂志,2022,28(3):41-44. [15] KO J H,JOO E J,PARK S J,et al.Neutralizing antibody production in asymptomatic and mild COVID-19 patients,in comparison with pneumonic COVID-19 patients[J/OL].J Clin Med,2020,9(7)[2022-12-27].http://doi.org/10.3390/jcm9072268. [16] WANG K,LONG Q X,DENG H J,et al.Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection[J]. Clin Infect Dis,2021,73(3):e531-e539. [17] 徐娜妮,胡小炜,李海燕,等.接种新型冠状病毒灭活疫苗血清抗体水平分析[J].预防医学,2022,34(1):33-37. [18] 华倩慧,徐校平,吕华坤,等.特定人群接种新冠病毒疫苗的安全性和有效性研究进展[J].预防医学,2022,34(5):479-482.
